Picard Medical, Inc. (PMI) Shareholder/Analyst Call Prepared Remarks Transcript
| Name | Quantity | Cost | Value | Profit ($) | Gain (%) |
|---|---|---|---|---|---|
Bobby Adusumilli SJS Investment Consulting Inc. | 3 | $3.12 | $0.45 | -$2.67 | -85.58% |
Kevin Kroskey True Wealth Design LLC | 28 | $30 | $4.21 | -$25.79 | -85.97% |
Alexandra Stickelman Root Financial Partners, LLC | 75 | $78 | $11.79 | -$66.21 | -84.88% |
Christopher C. Powers Farther Finance Advisors, LLC | 12 | $13 | $1.68 | -$11.32 | -87.08% |
Legacy Wealth Managment LLC/ID Legacy Wealth Managment LLC/ID | 50 | $88 | $7.2 | -$80.8 | -91.82% |
| Health Care Equipment & Supplies Industry | Healthcare Sector | Patrick N. J. Schnegelsberg CEO | AMEX Exchange | 71953R108 CUSIP |
| US Country | 75 Employees | - Last Dividend | - Last Split | - IPO Date |
Picard Medical, Inc. is a forward-thinking medical device company that focuses on the design, manufacture, and marketing of innovative healthcare solutions. Established in 2021, the company operates from its headquarters in Tucson, Arizona, and has a global footprint, serving markets in the USA and Europe, as well as other international regions. The company stands as a subsidiary of Hunniwell Picard I, LLC, leveraging its resources and expertise to advance the development of life-saving medical technologies, particularly in the field of artificial hearts.
The SynCardia Total Artificial Heart (TAH) is a groundbreaking medical device designed for patients diagnosed with advanced heart failure. It serves as a bridge to heart transplantation or, in certain cases, as a long-term solution to replace the failing human heart. This innovative product mimics the essential functions of a normal heart, allowing patients to regain their quality of life while awaiting a suitable donor organ. The TAH is recognized for its exceptional performance and is a testament to Picard Medical's commitment to improving patient outcomes in the field of cardiology.